Tutus, BeyzanurKaya, Aybuke ZuleyhaBaz, YoncaEvren, Asaf EvrimOzkan, Beguem Nurpelin SaglikYurttas, Leyla2024-09-182024-09-1820240272-43911098-2299https://doi.org/10.1002/ddr.22214https://hdl.handle.net/20.500.12483/7600In this study, the synthesis of N-(5,6-methylenedioxybenzothiazole-2-yl)-2-[(substituted)thio/piperazine]acetamide/propanamide derivatives (3a-3k) and to investigate their acetylcholinesterase (AChE), butyrylcholinesterase (BChE) and beta-secretase 1 (BACE-1) inhibition activity were aimed. Mass, H-1 NMR, and C-13 NMR spectra were utilized to determine the structure of the synthesized compounds. Compounds 3b, 3c, 3f, and 3j showed AChE inhibitory activity which compound 3c (IC50 = 0.030 +/- 0.001 mu M) showed AChE inhibitory activity as high as the reference drug donepezil (IC50 = 0.0201 +/- 0.0010 mu M). Conversely, none of the compounds showed BChE activity. Compounds 3c and 3j showed the highest BACE-1 inhibitory activity and IC50 value was found as 0.119 +/- 0.004 mu M for compound 3j whereas IC50 value was 0.110 +/- 0.005 mu M for donepezil, which is one of the reference substance. Molecular docking studies have been carried out using the data retrieved from the server of the Protein Data Bank (PDBID: 4EY7 and 2ZJM). Using in silico approach behavior active compounds (3c and 3j) and their binding modes clarified.eninfo:eu-repo/semantics/openAccessAlzheimer disease (AD)benzothiazolecholinesterase inhibitorsbeta-secretase (BACE-1)Article85410.1002/ddr.22214388169862-s2.0-85195013789Q2WOS:001235816600001N/A